DGAP-News: Symrise Executive Board members Heinrich Schaper and Jean-Yves Parisot early confirmed in office
DGAP-News: Symrise AG / Key word(s): Change of Personnel/Contract
Symrise Executive Board members Heinrich Schaper and Jean-Yves Parisot early confirmed in office
19.12.2018 / 10:00
The issuer is solely responsible for the content of this announcement.
The Supervisory Board of Symrise AG confirmed in advance the extension of the contracts of Executive Board members Heinrich Schaper and Dr. Jean-Yves Parisot. Both executives have been part of the management committee since 2016. The Supervisory Board thereby acknowledges the major contribution made by the two managers to the sustainable expansion of the operations of the Symrise segments Flavor and Nutrition, and the strategic alignment of the businesses to customer needs.
The contract of Flavor Board member Heinrich Schaper (62) is being extended in advance to 2022. Heinrich Schaper has been working for Symrise AG and its predecessor company for more than four decades now. Since 2016, he has been President of the Flavor segment. Heinrich Schaper has comprehensive experience in leading roles and has held positions in Germany and abroad. He has furthermore held various management functions in the United States and in the EAME region (Europe, Africa, Middle East). After obtaining a degree in Marketing and Industrial Management, he started his professional career as a Sales Manager for Flavors in 1978.
The contract of Nutrition Board member Dr. Jean-Yves Parisot (54) is being extended in advance until 2024. Since 2016, Jean-Yves Parisot has headed the Nutrition Segment that emerged from the takeover of the Diana Group in 2014. Prior to the acquisition and integration of Diana within Symrise AG, he headed the Food Division in the Diana Group for five years. He had previously worked in leading positions with several global chemicals, pharmaceuticals, and biotech companies, including at Air Liquide, Danisco and Rhodia. He started his career in Sales & Marketing at Pfizer. Jean-Yves Parisot studied Veterinary Medicine and has an MBA degree from HEC Paris.
Dr. Thomas Rabe, Chairman of the Supervisory Board of Symrise AG, said: "Our management team has two extraordinarily experienced and distinguished managers in Heinrich Schaper and Jean-Yves Parisot. We are therefore delighted to be able to provide advance confirmation of their positions. The continuous and dynamic development of the business has thereby been secured for the employees, customers and shareholders of Symrise."
About Symrise:
Symrise is a global supplier of fragrances, flavors, food and cosmetic ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, pharmaceuticals and producers of nutritional supplements and pet food.
Its sales of EUR 3 billion in the 2017 fiscal year make Symrise a leading global provider in the flavor, nutrition and fragrance markets. Headquartered in Holzminden, Germany, the Group is represented by around 100 sites in Europe, Africa, the Middle East, Asia, the United States and Latin America.
Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked as part of this process. Symrise - always inspiring more.
www.symrise.com
Social media:
twitter.com/symriseag linkedin.com/company/symrise youtube.com/agsymrise xing.com/companies/symrise
19.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Symrise AG |
|
Mühlenfeldstraße 1 |
|
37603 Holzminden |
|
Germany |
Phone: |
+49 (0)5531 90 0 |
E-mail: |
[email protected] |
Internet: |
www.symrise.com |
ISIN: |
DE000SYM9999, DE000SYM7787, DE000SYM7704 |
WKN: |
SYM999 |
Indices: |
MDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
|
End of News |
DGAP News Service |
754935 19.12.2018
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
2.996,29 |
3.154,03 |
3.407,85 |
3.520,45 |
3.825,69 |
4.618,48 |
4.730,19 |
EBITDA1,2 |
630,31 |
630,52 |
685,07 |
742,08 |
813,62 |
795,42 |
851,65 |
EBITDA-Marge3 |
21,04 |
19,99 |
20,10 |
21,08 |
21,27 |
17,22 |
|
EBIT1,4 |
431,59 |
433,97 |
455,35 |
487,51 |
558,96 |
503,98 |
559,36 |
EBIT-Marge5 |
14,40 |
13,76 |
13,36 |
13,85 |
14,61 |
10,91 |
11,83 |
Jahresüberschuss1 |
275,65 |
297,69 |
297,88 |
314,95 |
385,03 |
290,70 |
344,94 |
Netto-Marge6 |
9,20 |
9,44 |
8,74 |
8,95 |
10,06 |
6,29 |
7,29 |
Cashflow1,7 |
396,18 |
441,79 |
546,76 |
635,68 |
521,56 |
360,11 |
719,51 |
Ergebnis je Aktie8 |
2,06 |
2,08 |
2,12 |
2,22 |
2,70 |
2,00 |
2,44 |
Dividende8 |
0,88 |
0,90 |
0,95 |
0,97 |
1,02 |
1,10 |
0,85 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Ernst & Young
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Symrise |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
SYM999 |
99,920 |
Halten |
13.966,02 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
29,39 |
38,24 |
0,80 |
44,63 |
KBV |
KCV |
KUV |
EV/EBITDA |
4,02 |
19,41 |
2,95 |
19,53 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,10 |
1,10 |
1,10 |
15.05.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
25.04.2024 |
01.08.2024 |
24.10.2024 |
06.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-2,71% |
2,29% |
0,28% |
-7,65% |
|
|